We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

85 hedge funds and large institutions have $755M invested in Revance Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

4% more call options, than puts

Call options by funds: $728K | Put options by funds: $700K

4% more capital invested

Capital invested by funds: $727M → $755M (+$28.3M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

1% less funds holding

Funds holding: 86 → 85 (-1)

Holders
85
Holders Change
-1
Holders Change %
-1.16%
% of All Funds
2.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
32
Reduced
28
Closed
11
Calls
$728K
Puts
$700K
Net Calls
+$28K
Net Calls Change
+$161K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$9.74M
2
PC
Polar Capital
United Kingdom
+$3.1M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$2.25M
4
ACH
ArrowMark Colorado Holdings
Colorado
+$2.17M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.79M

Top Sellers

Rank Fund Capital Flow
1
PC
PointState Capital
New York
-$11.6M
2
GTC
Ghost Tree Capital
New York
-$2.36M
3
Franklin Resources
Franklin Resources
California
-$2.1M
4
JP Morgan Chase
JP Morgan Chase
New York
-$1.95M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
VC
26
Vivo Capital
California
$2.13M – – –
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$2.04M +$1.79M +73,862 New
EI
28
EAM Investors
California
$2M +$936K +38,621 +114%
QI
29
QS Investors
New York
$1.98M +$306K +12,607 +21%
TCIM
30
TIAA CREF Investment Management
New York
$1.66M +$14.4K +595 +1%
USAA
31
United Services Automobile Association
Texas
$1.63M +$35.1K +1,450 +3%
Allianz Asset Management
32
Allianz Asset Management
Germany
$1.59M +$37.3K +1,537 +3%
SCM
33
Suffolk Capital Management
New York
$1.46M -$412K -16,998 -24%
RCAMU
34
Rothschild & Co Asset Management US
Connecticut
$1.46M -$28.1K -1,158 -2%
Federated Hermes
35
Federated Hermes
Pennsylvania
$1.39M +$734K +30,285 +151%
PVI
36
Pura Vida Investments
New York
$1.38M +$1.21M +50,000 New
TA
37
Teachers Advisors
New York
$1.13M +$800 +33 +0.1%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$1.01M -$78.7K -3,248 -8%
Swiss National Bank
39
Swiss National Bank
Switzerland
$977K +$63K +2,600 +8%
PPA
40
Parametric Portfolio Associates
Washington
$966K +$144K +5,935 +20%
Victory Capital Management
41
Victory Capital Management
Texas
$956K -$3.88K -160 -0.5%
AA
42
ALPS Advisors
Colorado
$836K +$73.4K +3,027 +11%
NFA
43
Nationwide Fund Advisors
Ohio
$803K -$14.5K -600 -2%
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$753K +$86.1K +3,553 +15%
State of New Jersey Common Pension Fund D
45
State of New Jersey Common Pension Fund D
New Jersey
$716K – – –
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$705K +$6.54K +270 +1%
CS
47
Credit Suisse
Switzerland
$670K +$285K +11,767 +93%
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$642K – – –
Ameriprise
49
Ameriprise
Minnesota
$634K +$1.94K +80 +0.3%
ARTA
50
A.R.T. Advisors
New York
$630K +$272K +11,200 +96%
1
2
3 4

RVNC Hedge Fund Activity: Q3 2017 in Review

85 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2017, worth a combined $755M — up 3.9% from $727M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of RVNC and 10 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 32 added.

The largest buyer was Wellington Management Group, adding an estimated $9.74M. The largest seller was PointState Capital, exiting entirely with an estimated $11.6M sold.

  • 85 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2017, down from 86 in Q2 2017.
  • Funds reported $755M of Revance Therapeutics, Inc. stock for Q3 2017, up 3.9% quarter-over-quarter.
  • 10 funds opened new Revance Therapeutics, Inc. positions in Q3 2017 and 11 closed out, a net change of -1 holder.
  • The largest Revance Therapeutics, Inc. buyer in Q3 2017 was Wellington Management Group, an estimated $9.74M added.
  • The largest Revance Therapeutics, Inc. seller in Q3 2017 was PointState Capital, an estimated $11.6M sold.

Based on aggregated 13F filings for Q3 2017.